Regeneron Pharmaceuticals (REGN) Interest & Investment Income (2009 - 2026)
Regeneron Pharmaceuticals (REGN) posted quarterly Interest & Investment Income of -$48.0 million for Q2 2026, down 317.19% year-over-year from $22.1 million in Q2 2025, and up 27.05% quarter-over-quarter from -$65.8 million in Q1 2026.
Regeneron Pharmaceuticals (REGN) Interest & Investment Income (2009 - 2026) Analysis & Trends
Regeneron Pharmaceuticals' Interest & Investment Income history runs 18 years deep, the most recent figure standing at -$48.0 million for Q2 2026.
- In Q2 2026, Interest & Investment Income fell 317.19% year-over-year to -$48.0 million; the TTM figure through Jun 2026 stood at -$91.0 million (down 174.35% YoY), while the FY2025 annual figure was $83.0 million, up 12.77% from the prior year.
- Interest & Investment Income for Q2 2026 stood at -$48.0 million, up from -$65.8 million in the prior quarter.
- The five-year high for Interest & Investment Income was $128.2 million in Q3 2024, with the low at -$144.9 million in Q1 2022.
- The 5-year median for Interest & Investment Income is $7.5 million (2024), against an average of -$700000.0.
- The sharpest annual moves came in 2022 and 2025: Interest & Investment Income slumped 6612.5% in 2022, then jumped 988.57% in 2025.
- Regeneron Pharmaceuticals' Interest & Investment Income stood at $36.3 million in 2022, then soared by 162.81% to $95.4 million in 2023, then plunged by 169.18% to -$66.0 million in 2024, then soared by 110.76% to $7.1 million in 2025, then slumped by 776.06% to -$48.0 million in 2026.
- Business Quant data shows REGN's Interest & Investment Income at -$48.0 million in Q2 2026, -$65.8 million in Q1 2026, and $7.1 million in Q4 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Int & Inv Inc (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 120.60 Mn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | -48.00 Mn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 48.00 Mn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 35.58 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 27.90 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | - |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 5.13 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 28.14 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 10.98 Mn |
| 10 | Roivant Sciences | 26.16 Bn | 26.85 Bn | 1.16 Mn | 36.92 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -48.00 Mn |
| Mar 31, 2026 | -65.80 Mn |
| Dec 31, 2025 | 7.10 Mn |
| Sep 30, 2025 | 15.70 Mn |
| Jun 30, 2025 | 22.10 Mn |
| Mar 31, 2025 | 38.10 Mn |
| Dec 31, 2024 | -66.00 Mn |
| Sep 30, 2024 | 128.20 Mn |
| Jun 30, 2024 | 7.90 Mn |
| Mar 31, 2024 | 3.50 Mn |
| Dec 31, 2023 | 95.40 Mn |
| Sep 30, 2023 | 21.30 Mn |
| Jun 30, 2023 | -15.70 Mn |
| Mar 31, 2023 | 57.20 Mn |
| Dec 31, 2022 | 36.30 Mn |
| Sep 30, 2022 | -51.30 Mn |
| Jun 30, 2022 | -53.70 Mn |
| Mar 31, 2022 | -144.90 Mn |
| Dec 31, 2021 | -35.90 Mn |
| Sep 30, 2021 | -6.40 Mn |